title: Endometrial stromal sarcoma arising from endometriosis: a clinicopathological study and literature review.
abstract: OBJECTIVE
  We aimed to investigate the nature of endometrial stromal sarcoma (ESS) arising from endometriosis.
  
  
  METHODS
  The clinical data of 5 patients with ESS arising from endometriosis were reviewed retrospectively. The expression of CD117, HER2/neu, EGFR, VEGF, and PDGFR was analyzed by immunohistochemical staining.
  
  
  RESULTS
  The median age of the 5 patients was 45 years. The primary tumor sites were the ovary in 2, the pelvis in 2, and the cervical canal in 1 patient. Three patients had disseminated disease at diagnosis. Four patients underwent complete tumor resection. All of the 5 cases received adjuvant chemotherapy and 2 received progesterone therapy, while none were treated with radiotherapy. No recurrence occurred in the 4 cases who had complete tumor resection, and the only patient who progressed was the patient in whom the tumor was unresectable. Tumor cells in all cases exhibited positive staining for PDGFR and were negative for CD117 and HER2/neu. The expression of EGFR and VEGF was observed in 2 and 4 cases, respectively.
  
  
  CONCLUSIONS
  ESS arising from endometriosis is rare. Complete tumor resection in ESS arising from endometriosis may reduce the recurrence rate.
authors.affiliation: State Key Laboratory of Oncology in South China, Guangzhou, PR China.
authors.forename: Chunyan
authors.initials: C
authors.lastname: Lan
authors.forename: Xin
authors.initials: X
authors.lastname: Huang
authors.forename: Suxia
authors.initials: S
authors.lastname: Lin
authors.forename: Muyan
authors.initials: M
authors.lastname: Cai
authors.forename: Jihong
authors.initials: J
authors.lastname: Liu
mesh_terms: D000328:Adult; D017024:Chemotherapy, Adjuvant; D016889:Endometrial Neoplasms / Q000209:etiology / Q000378:metabolism / Q000628:therapy*; D004715:Endometriosis / Q000150:complications*; D066246:ErbB Receptors / Q000378:metabolism; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000209:etiology / Q000378:metabolism / Q000628:therapy*; D010386:Pelvic Neoplasms / Q000209:etiology / Q000378:metabolism / Q000628:therapy*; D019009:Proto-Oncogene Proteins c-kit / Q000378:metabolism; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D017479:Receptors, Platelet-Derived Growth Factor / Q000378:metabolism; D018203:Sarcoma, Endometrial Stromal / Q000209:etiology / Q000378:metabolism / Q000628:therapy*; D002583:Uterine Cervical Neoplasms / Q000209:etiology / Q000378:metabolism / Q000628:therapy*; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism; D055815:Young Adult
chemical_list: D066246:ErbB Receptors; D019009:Proto-Oncogene Proteins c-kit; D018719:Erb-b2 Receptor Tyrosine Kinases; D017479:Receptors, Platelet-Derived Growth Factor; D042461:Vascular Endothelial Growth Factor A; C508053:ERBB2 protein, human